pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LEQEMBI · news · pharmadog
← back to LEQEMBI
News mentioning LEQEMBI
13
stories
Jul 30, 26
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
Jul 29, 26
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
Jul 29, 26
Leqembi records best quarter since launch as Biogen raises underlying guidance
endpoints
Jul 23, 26
Biogen counts on drugs from Apellis deal to patch Leqembi's slow sales
endpoints
Jul 14, 26
Erasca's $550M offering; Summit sells an antibiotic
endpoints
Jul 14, 26
STAT+: Akero team, backed by Fairmount, launches new immunology company
stat
Jul 14, 26
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
biopharma dive
May 11, 26
STAT+: Medicare’s miss on Alzheimer’s drug spending
stat
May 11, 26
STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
stat
May 11, 26
STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
stat
May 8, 26
FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering
endpoints
May 8, 26
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
biopharma dive
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive
